VCNXOTCPharmaceutical PreparationsFiscal year ends December 31

VACCINEX, INC.

Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025

$1.00−0.01 (-0.99%)

Close on Oct 19, 2026

Market cap: $3.22M
P/E (TTM): –
Dividend yield: –

VACCINEX, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Revenue	0.60	0.57	0.28	0.90	0.63	0.52	0.72	0.09	–
Cost of Revenue	–	–	–	–	0.00	0.20	1.03	0.16	–
Gross Profit	–	–	–	–	0.62	0.32	-0.31	-0.07	–
Research & Development	13	17	14	17	22	26	22	17	–
General & Administrative	6.79	6.88	6.20	6.23	7.41	6.67	4.62	4.48	–
Total Costs & Expenses	19	23	20	23	29	33	28	21	–
Operating Income	-19	-23	-20	-22	-28	-32	-27	-21	–
Interest Expense	0.00	0.00	0.00	0.81	0.49	–	0.39	1.36	–
Other Non-Operating Income	0.04	0.91	0.09	0.04	-0.03	0.15	0.17	-0.04	–
Asset Impairment Charges	0	0	0	0	0	0	0	0	–
Pretax Income	-19	-20	-20	-22	-29	-32	-30	-19	–
Income Tax Expense	0	0	0	0	0	0	0	0	0
Net Income incl. Noncontrolling Interests	-19	-20	-20	-22	-29	-32	-30	-19	–
Minority Interest in Earnings	–	–	–	0	0	0	0	-0.04	–
Net Income	-19	-20	-20	-22	-29	-32	-30	-19	–
Preferred Dividends	–	–	–	–	–	–	0	3.21	–
EPS (Basic)(per share)	-8.88	-43.68	-98.05	-163.80	-323.40	-518.70	-1,186.50	-4,179.00	–
EPS (Diluted)(per share)	-8.88	-43.68	-98.05	-163.80	-323.40	-518.70	-1,186.50	-4,179.00	–
Shares Outstanding (Basic, Weighted)(shares)	2.10	0.46	0.20	0.14	0.09	0.06	0.02	0.01	–
Shares Outstanding (Diluted, Weighted)(shares)	2.10	0.46	0.20	0.14	0.09	0.06	0.02	0.01	–
EBITDA	–	–	–	–	–	-32	-27	-21	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2024

Profitability, TTM

Gross margin: –
Operating margin: -3117.3%
Net margin: -3100.5%
Return on equity, FY2024: –

Financial strength

Current ratio: 0.50
Debt to equity: –
Debt to assets: 1.0%
Cash to current liabilities: 21.8%

Valuation

P/E ratio: –
Price to sales: 5.36
Price to book: –
Dividend yield: –